Latest Breaking News On - ஆய்வகங்கள் இஸ்ரேல் - Page 3 : comparemela.com

Panaxia Israel announces estimated record revenues of at least 19 million in Q1 2021

Panaxia Israel announces estimated record revenues of at least 19 million in Q1 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Dadi segalSegal pharma groupPanaxia pharmaceutical industriesPanaxia labs israel ltdIsraeli ministry of healthPanaxia globalPanaxia labs israelPanaxia israelLabs israelIsraeli ministryடாடி ஸீகல்ஸீகல் பார்மா குழுஇஸ்ரேலி அமைச்சகம் ஆஃப் ஆரோக்கியம்ஆய்வகங்கள் இஸ்ரேல்இஸ்ரேலி அமைச்சகம்

הסטארט-אפ הישראלי רדיס לאבס שעובד עם פדקס, נטפליקס וגאפ שווה 2 מיליארד דולר

הסטארט-אפ הישראלי רדיס לאבס שעובד עם פדקס, נטפליקס וגאפ שווה 2 מיליארד דולר
themarker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarker.com Daily Mail and Mail on Sunday newspapers.

Israel labsLabs israelஆய்வகங்கள் இஸ்ரேல்

Panaxia closes out 2020 tripling revenues to a record breaking 60 7 million

Share this article LOD, Israel, April 5, 2021 /PRNewswire/ Dadi Segal, CEO of Panaxia, said, We are delighted to cap a successful year of strong growth in our activity in the Israeli market, despite the increasing competition in the industry. We reached a peak by achieving the milestones required for exports from Israel and initial commercial export of our products to Germany. We expect 2021 to be a breakthrough year for Panaxia in the German market and in Europe in general, with our recent selection as the main supplier in the prestigious French government program and as a supplier to the government of Cyprus, which are both strong expressions of regulatory faith in the quality of our products. This year, we plan to continue implementing our strategic plans to expand into Europe and other countries, while focusing on production and marketing of our premium products, as well as the local market and exports.

Prnewswire dadi segalSegal pharma groupPanaxia pharmaceutical industriesPanaxia labs israel ltdIsraeli ministry of healthPanaxia globalPanaxia labs israelIsraeli ministryPanaxia israelLabs israelஸீகல் பார்மா குழுஇஸ்ரேலி அமைச்சகம் ஆஃப் ஆரோக்கியம்இஸ்ரேலி அமைச்சகம்ஆய்வகங்கள் இஸ்ரேல்

Government of Cyprus selects Israeli company Panaxia: Will purchase its premium oils for the country s medical cannabis patients

( Panaxia Israel ) (TASE: PNAX), Israel s largest manufacturer of medical cannabis products, today announced that it was selected by the government of Cyprus to supply premium oils it has developed under the Panaxir brand for medical cannabis patients in the country. In recent months, talks between the government of Cyprus and Panaxia had been ongoing, and yesterday the company received final approval for an order and import permits for the products. As part of the agreement, Panaxia will initially export two types of medical cannabis oil in different concentrations from its premium line, which are produced according to EU-GMP requirements and according to strict pharmaceutical standards. In the future, the option of expanding the range of products will be examined.

Noa levielSegal pharma groupPanaxia labs israel ltdPanaxia pharmaceutical industriesIsraeli ministry of healthNarcotic drugsPsychotropic substancesPharmaceutical cannabisPanaxia israelLabs israelIsraeli ministryஸீகல் பார்மா குழுஇஸ்ரேலி அமைச்சகம் ஆஃப் ஆரோக்கியம்போதை மருந்துகள்மருந்து கஞ்சாஆய்வகங்கள் இஸ்ரேல்

Unprecedented international achievement for Panaxia: selected as one of the four main winners in the French government tender for regulation of the medical cannabis industry

Share this article TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ Dr. Dadi Segal, CEO of Panaxia Global, said, Our success in this prestigious French government tender along with our partner, Neuraxpharm, is a huge achievement for Panaxia, and we are proud to be part of the elite group of global medical cannabis leaders selected for the program. The fact that four Panaxia products met the French regulatory requirements, including sublingual tablets for the first time, serves as powerful confirmation of the uncompromising quality of the company s products. We believe the French market will become one of the world s most advanced medical cannabis markets as well as a significant growth driver for Panaxia. We are excited to take our first steps there and provide the patients in the program with innovative and quality cannabis products.

United kingdomDadi segalMalgorzata gosia meunierThomas dierksNoa levielNational agency for the safety of medicinesSegal pharma groupPanaxia labs israel ltdPanaxia pharmaceutical industriesIsraeli ministry of healthHealth productsPanaxia globalLabs israel ltdNational agencyAlongside israeliAustralian little green